Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Clinical trial NCT04223856 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04223856
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-30
- Primary completion
- 2023-08-08
- Enrollment
- 886
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.